Theodorescu receives prestigious Barringer Medal

April 24, 2015

Dan Theodorescu, MD, PhD, director of the NCI-designated University of Colorado Cancer Center and professor of Urology and Pharmacology at the University of Colorado School of Medicine was awarded the Barringer Medal this past Saturday from the American Association of Genitourinary Surgeons for his distinguished contributions to urology.

"I am honored beyond measure to receive this award from an institution that I greatly respect and admire," Theodorescu says.

Every year, the Barringer Medal is awarded to a urologic surgeon for outstanding contributions to the field. The first award in 1955 went to Charles Huggins, the only urologist to ever have won a Nobel Prize, for his discovery of the hormonal sensitivity of tumors. Traditionally, the black-tie award presentation opens with pictures of the recipient as a child.

"I was surprised when I recognized myself in the first picture!" says Theodorescu, though he mentions he found it a bit suspicious when his wife, who was party to the surprise, insisted on joining him in San Francisco for this year's annual meeting.

"I'm frugal, so usually I skip the black tie event, but this year I had to adjust other travel plans to include it since Diane wanted to attend," he says. "I guess she and the awards committee had been plotting this for months..."

Dr. Theodorescu is an internationally recognized expert in the biology and treatment of bladder cancer. In addition to directing the CU Cancer Center, Theodorescu manages an active translational molecular biology lab focused on identifying the mechanisms leading to bladder cancer growth and spread and their potential applications to patients with this disease.

Theodorescu has been involved in the development and testing of COXEN (CO-eXpression ExtrapolatioN), a radical new personalized medicine strategy that aims to predict which tumors will be sensitive to which drugs based on genetic analysis of tumor samples. He also led the team that in 2014 described the first drug against Ral, an oncogene that contributes to drive several cancer types including pancreas, lung, colon, bladder and prostate.

Created in 1954, the award honors Benjamin S. Barringer, the first chief of urology at what is now the Memorial Sloan Kettering Cancer Center in New York City. Barringer was an early innovator of brachytherapy in 1915, in which radium needles were used to treat prostate cancer.

"I see the award not as a pat on the back but as incentive to work even harder toward understanding the causes and best treatments for cancer, which has been my childhood dream," Theodorescu says.
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.